Alpine Immune Sciences (ALPN) Stock Price
Alpine Immune Sciences Price
Over the last 8 years Alpine Immune Sciences grew revenue by 81.9% annually, reaching 58.88 M USD. For Alpine Immune Sciences, the net margin of -54.7% is up versus -2,444.5% a few years ago.
Alpine Immune Sciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Alpine Immune Sciences business model & stock analysis
Frequently asked questions about Alpine Immune Sciences
The business model of Alpine Immune Sciences Inc revolves around its innovative approach to developing and commercializing immunotherapies. As a biopharmaceutical company, Alpine Immune Sciences focuses on discovering and developing a diverse array of next-generation immunotherapies using its proprietary Variant Immunoglobulin Domain (vIgD) platform. This platform allows the company to generate novel therapeutic candidates with enhanced efficacy and safety profiles. Alpine Immune Sciences aims to address unmet medical needs by advancing these candidates through preclinical and clinical stages, ultimately shaping the future of immunotherapy.
Alpine Immune Sciences Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Alpine Immune Sciences Inc in the market include companies like Gilead Sciences, Inc., AstraZeneca Plc, Roche Holding AG, and Novartis AG.
Alpine Immune Sciences Inc, founded in 2015, is a clinical-stage biopharmaceutical company based in Seattle, Washington. The company focuses on discovering, developing, and commercializing next-generation immunotherapies for cancer and autoimmune diseases. Alpine utilizes its proprietary Variant Immunoglobulin Domain (vIgD) platform to create novel therapeutic molecules. These molecules exhibit enhanced targeting, improved safety profiles, and potent immune-stimulating properties. With a diverse pipeline encompassing multiple therapeutic areas, Alpine Immune Sciences Inc is dedicated to revolutionizing the treatment of various diseases through innovative immunotherapies. Their commitment to cutting-edge research and development makes Alpine a promising player in the biopharmaceutical industry.
Alpine Immune Sciences Inc has achieved several significant milestones. The company successfully completed a Phase I clinical trial for its lead product candidate, ALPN-101, demonstrating favorable safety and pharmacokinetics. Alpine also received FDA clearance to initiate a Phase I/II clinical trial for ALPN-101 in patients with autoimmune and inflammatory diseases. Additionally, Alpine entered into a strategic collaboration and license agreement with AbbVie to develop and commercialize ALPN-101. These milestones highlight the company's progress in advancing its innovative immunotherapies and building strong partnerships within the biopharmaceutical industry.
Alpine Immune Sciences Inc is primarily present in the United States.
Alpine Immune Sciences Inc represents values of innovation, collaboration, and scientific excellence. With a dedicated team of experts, the company is committed to advancing the field of immunology through its unique platform technology and novel therapeutics. Alpine Immune Sciences Inc prioritizes the development of transformative medicines to address unmet medical needs and improve patient outcomes. By leveraging its proprietary discovery engine, the company aims to revolutionize the treatment options for various diseases. Alpine Immune Sciences Inc's corporate philosophy revolves around fostering partnerships and driving meaningful advancements in the field of immunotherapy.
15 analysts currently rate the Alpine Immune Sciences stock: 8 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Alpine Immune Sciences to generate revenue of 8.98 M USD and earnings per share of -2.26 USD.
Converted at the current exchange rate, the Alpine Immune Sciences share trades at 58.18 EUR (64.97 USD).
The Alpine Immune Sciences share (ALPN) is listed on 5 stock exchanges, including: NASDAQ (ALPN), SIX (Zürich) (34LA.SW), Frankfurt (34LA.F), München (34LA.MU), Düsseldorf (34LA.DU).
Alpine Immune Sciences Inc is a biopharmaceutical company focused on the development of immunotherapies for a variety of diseases. The company is headquartered in Seattle, Washington, and is listed on NASDAQ under the ticker ALPN. The business model of Alpine Immune Sciences is based on the discovery and development of novel immunomodulatory proteins that can be used to treat cancer, inflammation, and autoimmune diseases. The company has developed a patented platform called Variant Immunoglobulin Domain (vIgD), which allows it to identify and develop a variety of proteins that target the immune system. One of the company's key products is ALPN-101, a highly effective immunomodulatory protein therapy that can be used to treat autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and others. Alpine Immune Sciences is also developing a range of cancer therapeutics based on vIgD. These therapeutics have the potential to directly attack and destroy tumor cells by targeting the patient's immune system. Alpine Immune Sciences is also pursuing a strategy of collaboration with other pharmaceutical companies to accelerate the development and commercialization of its therapeutics. The company has already entered into a partnership with AbbVie to develop a highly effective cancer immunotherapy. The business model of Alpine Immune Sciences is focused on developing novel and effective immunotherapies that have the potential to treat a variety of diseases. The company aims to utilize its patented platform technology to identify and develop innovative immunotherapies and further advance these therapies through targeted clinical trials. Alpine Immune Sciences has experienced impressive growth in recent years and is expected to continue to be successful in the coming years by focusing on the development of novel therapeutics. By collaborating with other pharmaceutical companies and focusing on the development of therapeutics for a variety of diseases, the company is likely to continue to be successful.
The expected revenue of Alpine Immune Sciences is 8.98 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Alpine Immune Sciences is -112.75 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Alpine Immune Sciences is currently -28.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alpine Immune Sciences stock.
The price-to-sales ratio (P/S) of Alpine Immune Sciences is currently 361.67. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alpine Immune Sciences stock.
The Eulerpool Quality Score for Alpine Immune Sciences is 5/10.
The ISIN of Alpine Immune Sciences is US02083G1004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Alpine Immune Sciences is A2DU89. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Alpine Immune Sciences is ALPN. The ticker symbol is used to trade Alpine Immune Sciences shares on the stock exchange.
Alpine Immune Sciences stock
Alpine Immune Sciences Peer Group
Alpine Immune Sciences Ticker
Alpine Immune Sciences FIGI
All fundamentals and in-depth analysis of Alpine Immune Sciences
Our stock analysis for Alpine Immune Sciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alpine Immune Sciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.